TH18318B - Substituted thiazoleidionic derivatives - Google Patents

Abstract

This invention focuses on compounds of formula (I) (chemical formula) (l) or the totomeric form of this substance and/or solvents that are acceptable in pharmaceutical of this substance, where R1 is the hydrogen atom, alkyl group, acyl group, aralkyl group, where MoiAT This Aryl may replace or can not replace or the Aryl group that replaced or was not Can be substituted. A1 is Hydrogen, or can be chosen as a 1-4 selectable group from a group. containing alkyl, alkoxy, aryl and halogens, or A1 is a replacement group. two groups on adjacent carbon atoms in which this replacement group is shared with atoms. The bonded carbon when arranged as the substituted or irreplaceable aryl group, A2 is ringbenzene chosen to have 1-3 groups in place, and M is the counter ion. The invention involved some new compounds. process for preparation of these compounds pharmaceutical ingredients (pharmaceutical composition) containing such compounds and the use of these compounds and ingredients in medicines, patent medicines

Claims (8)

1. Maliic acid salt compound of 5- [4- [2- (N-methyl-N- (2- pyridyl) amino) ethoxy] benzyl] thiazo. Lidine-2,4-dion Or isomer or inositomeric form of this substance and / or the solvate of this substance that is pharmacologically acceptable. 2. The preparation process for the preparation of 5- [4- [2- (N-Methyl-N- (2- pyridyl) amino) ethoxy] benzyl) salts of 5 Maliic acid salts. ] Thiazoleidine 2,4-dion Or isomers Or inositol form of this substance and / or solvate of this substance Acquired in pharmaceuticals The process consists of a reaction of 5- [4- [2- (N-methyl-N- (2- pyridyl) amino) ethoxi] benzyl] thiazoli. Dean 2,4-Dion With the source of the Maliate ion HOOC.CH = CH.COO-; And from there if needed Prepare a solvate of this substance that is pharmacologically acceptable. 3. Pharmaceutical ingredients (pharmaceutical composition), which includes salts of Maliic acid of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] hyazolidine -2,4 dion or iso Mercedes Or the inositol form of this substance and / or the solvate of this substance, which is pharmacologically acceptable and the carrier of this substance is pharmacologically acceptable. 4. Maliic acid salts. 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine -2,4 dion or iso Mercedes Or inositol form of this substance and / or solvate of this substance Acceptable in pharmaceutical field for use as Therapeutic active substances 5. Maliic acid salts. 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] hyazolidine -2,4 dion or iso Mercedes The inositol or inositol form of this substance and / or the solvate of it is pharmacologically acceptable for use in the treatment and / or prevention of hyperglycemia. Excessive blood cholesterol, high blood pressure and cardiovascular disease. 6. Salt Use the salt of Maliic acid of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine -2,4 dion or iso The polymer or inositol form of this substance and / or its solvates are acceptable for the manufacture of pharmaceuticals for the treatment and / or prevention of hyperglycemia, hyperlipidemia, hyperlipidemia. High pressure and disease related to the heart and blood vessels 7. Compound of formula (I): (chemical formula) (l) or inositol form of this compound where R1 represents the C1-C12 alkyl hydrogen atom, C1-C12 alkoxy, C1-C12 Al. Alkyl carbonyl or aryl C1-C12 alkyl; A1 represents hydrogen or 1 to 4 optional types of substitute groups selected from. The group consists of: C1-C12 alkyl, C1-C12 alkoxy, aryl and halogen; Selective aryltons, phenyls, or naphthyls were replaced with halogen-based selective groups, C1-C12 alkyl, phenyl, C1-C12 alkoxy, C1-C12 halos. Alkyl hydroxy, nitro, C1-C12 alkoxy carbonyl, C1-C12 alkoxy carbonyl, C1-C12 alkyl, C1-C12 alkoxy Carbonyloxi, or C1-C12 alkyl carbonyl up to 5 groups; A2 represents a benzene band with 1 to 3 selectable replacement groups selected from hydrogen, halogen, C1-C12 alkyl, C1-C12 alkoxy, and M instead of counter ions. Beyond Maliethion 8. Process for the compound preparation of formula (I) according to claim 7 or the monomeric weave of this compound. Which the process of combining Compound reaction of formula (II): (chemical formula) where R1, A1 and A2 are defined, relative to the formula (I) in claim 7, with the source of counter Ion M, which is determined. In relation to the formula (I) as set out in claim 7